<DOC>
	<DOCNO>NCT00032162</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine liposomal doxorubicin carboplatin treat patient gynecologic cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Carboplatin Treating Patients With Gynecologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose doxorubicin HCl liposome administer carboplatin patient gynecological tumor . - Determine dose-limiting toxicity regimen patient . - Determine kind , frequency , severity , duration adverse event patient treat regimen . OUTLINE : This multicenter , dose-escalation study doxorubicin HCl liposome . Patients receive doxorubicin HCl liposome IV 60 minute follow carboplatin IV 30 minute day 1 . Treatment repeat every 28 day 6 course . Cohorts 3-6 patient receive escalate dos doxorubicin HCl liposome maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue treated MTD . Patients follow 4-6 week every 3 month thereafter . PROJECTED ACCRUAL : A total 12-24 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm fallopian tube cancer , Muellerian mixed tumor , endometrial cancer , uterine sarcoma , ovarian cancer sarcoma part , cervical cancer No ovarian epithelial cancer PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 10.0 g/dL Hepatic : Bilirubin great 1.25 time upper limit normal Renal : Glomerular filtration rate least 60 mL/min Cardiovascular : No atrial ventricular arrhythmia No congestive heart failure even stabilize medication No New York Heart Association class III IV heart disease No myocardial infarction within past 6 month Other : No preexist sensory motor neuropathy grade 2 great No active infection No serious medical condition would preclude study Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : No 1 prior chemotherapy regimen malignancy No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy within past 10 day allow No concurrent hormonal therapy Radiotherapy : At least 6 week since prior radiotherapy 25 % bone marrow Surgery : Not specify Other : At least 30 day since prior experimental agent No concurrent therapy would preclude study No concurrent participation another study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IA cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage I endometrial carcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>stage I uterine sarcoma</keyword>
	<keyword>stage II uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian carcinosarcoma</keyword>
</DOC>